Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis (Q38262622)

1 September 2017

6 references

25 April 2019

30 June 2019

27 September 2019

27 November 2019

13 December 2019

29 October 2020

0 references

Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis (English)

1 reference

relapsing-remitting multiple sclerosis

1 September 2017

6 references

25 April 2019

30 June 2019

27 September 2019

27 November 2019

13 December 2019

29 October 2020

0 references

1 reference

27 September 2019

1 reference

27 November 2019

1 reference

13 December 2019

1 reference

29 October 2020

1

Hans-Peter Hartung

1 reference

1 September 2017

Orhan Aktas

2

1 reference

PMCID

4361497

1 September 2017

Alexey N Boyko

series ordinal

3

1 reference

1 September 2017

24 October 2014

1 reference

PMCID

4361497

Multiple Sclerosis Journal

1 September 2017

1 January 2015

6 references

25 April 2019

30 June 2019

27 September 2019

27 November 2019

13 December 2019

29 October 2020

7 references

1 September 2017

25 April 2019

30 June 2019

27 September 2019

27 November 2019

13 December 2019

29 October 2020

21

1 reference

1 September 2017

22-34

1 reference

1 September 2017

1

1 reference

Creative Commons Attribution-NonCommercial 3.0 Unported

1 September 2017

6 references

25 April 2019

30 June 2019

27 September 2019

27 November 2019

13 December 2019

on focus list of Wikimedia project

29 October 2020

ScienceSource

0 references

cites work

Accelerated lymphocyte recovery after alemtuzumab does not predict multiple sclerosis activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4361497

Insights into the Mechanisms of the Therapeutic Efficacy of Alemtuzumab in Multiple Sclerosis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4361497

Risk evaluation and monitoring in multiple sclerosis therapeutics

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4361497

Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4361497

Multiple sclerosis: Prospects and promise

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4361497

Immune competence after alemtuzumab treatment of multiple sclerosis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4361497

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4361497

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4361497

B cells and antibodies in multiple sclerosis pathogenesis and therapy

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4361497

Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4361497

Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4361497

A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4361497

Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4361497

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4361497

Autoimmunity during lymphopenia: a two-hit model

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4361497

Case report of anti-glomerular basement membrane disease following alemtuzumab treatment of relapsing-remitting multiple sclerosis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4361497

Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4361497

Predicting autoimmunity after alemtuzumab treatment of multiple sclerosis.

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4361497

Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis.

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4361497

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4361497

Impact of alemtuzumab treatment on the survival and function of human regulatory T cells in vitro.

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4361497

Immune status following alemtuzumab treatment in human CD52 transgenic mice.

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4361497

Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity.

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4361497

Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model.

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4361497

Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis.

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4361497

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

31 August 2018

1 reference

Crossref

https://api.crossref.org/works/10.1177%2F1352458514549398

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

21 January 2018

1 reference

PubMed

12 December 2020

Anti-glomerular basement membrane disease after alemtuzumab

1 reference

PubMed

12 December 2020

Evolution of multiple sclerosis treatment: next generation therapies meet next generation efficacy criteria

1 reference

PubMed

12 December 2020

1 reference

12 December 2020

Identifiers

DOI

10.1177/1352458514549398

1 reference

1 September 2017

1 reference

1 September 2017

1 reference

PMCID

4361497